Cannabis Clinical Trials: Research, Regulations, and Current Studies

Executive Summary

Cannabis clinical trials represent the frontier where botanical medicine meets evidence-based regulatory approval, with over 200 active studies worldwide as of July 2026 investigating cannabinoid therapies for conditions ranging from chemotherapy-induced peripheral neuropathy to epilepsy and chronic pain. The July 2026 dosing of the first patient in Ananda Pharma's NIHR-backed CIPN trial marks a milestone in UK cannabis research, joining a growing body of FDA-approved Investigational New Drug applications and international Phase II/III studies. Despite cannabis remaining a Schedule I controlled substance under the Controlled Substances Act (21 U.S.C. § 812), the Drug Enforcement Administration has licensed dozens of domestic cultivators to supply research-grade material, while the Food and Drug Administration has approved three cannabinoid-based drugs—Epidiolex, Marinol, and Syndros—through the traditional clinical trial pathway. The global cannabis clinical trial market reached $1.2 billion in 2025, with pharmaceutical companies, academic medical centers, and specialized contract research organizations racing to generate the double-blind, placebo-controlled data required for regulatory approval in major markets.

Why This Matters

Clinical trials are the only pathway to FDA approval for cannabis-derived medications, directly impacting 128 million Americans living in medical cannabis states who currently access products without pharmaceutical-grade quality controls or physician dosing guidance. For patients with chemotherapy-induced peripheral neuropathy alone—affecting up to 68% of cancer survivors according to National Cancer Institute data—the absence of FDA-approved cannabinoid treatments forces reliance on state-licensed dispensaries offering products with inconsistent cannabinoid profiles and minimal clinical oversight.

The financial stakes are substantial. Wall Street analysts project the FDA-approved cannabinoid pharmaceutical market could reach $18 billion by 2030, compared to the $33 billion state-licensed market. Institutional investors including Merck, Pfizer, and GW Pharmaceuticals (now Jazz Pharmaceuticals) have collectively invested over $4.7 billion in cannabinoid drug development since 2018. The success or failure of ongoing Phase III trials will determine whether cannabis transitions from a state-regulated botanical product to a federally legal prescription medication covered by Medicare, Medicaid, and private insurance.

For the 38 states with medical cannabis programs, clinical trial outcomes directly influence formulary decisions and physician prescribing patterns. The 2018 FDA approval of Epidiolex for Dravet syndrome and Lennox-Gastaut syndrome demonstrated that rigorous clinical evidence can overcome Schedule I classification—Epidiolex generated $888 million in 2025 sales despite competing with state-licensed CBD products. Each successful trial expands the evidence base supporting rescheduling petitions and provides ammunition for advocates challenging the DEA's continued Schedule I classification.

Background and History: From Prohibition to Protocol

The modern era of cannabis clinical trials began not with legalization but with the 1970 Controlled Substances Act, which simultaneously criminalized cannabis as Schedule I and established the regulatory framework for researching it. The designation—reserved for substances with "no currently accepted medical use and a high potential for abuse"—created a paradox: proving medical use required clinical trials, but Schedule I status made conducting those trials extraordinarily difficult.

The NIDA Monopoly Era (1968-2021)

From 1968 until May 2021, the National Institute on Drug Abuse maintained the only federally legal cannabis cultivation facility at the University of Mississippi, creating a research bottleneck that persisted for 53 years. Scientists seeking to conduct FDA-compliant clinical trials faced a multi-year approval process requiring sign-off from the DEA, FDA, NIDA, and institutional review boards. The University of Mississippi facility produced cannabis with THC concentrations rarely exceeding 13%, while state-licensed dispensaries sold products testing above 30% THC—rendering much federally funded research clinically irrelevant to real-world use patterns.

Dr. Lyle Craker's 2001 petition to the DEA for a license to cultivate research cannabis at the University of Massachusetts became a landmark case. After a 2007 administrative law judge recommended approval, the DEA denied the application in 2009, citing the international Single Convention on Narcotic Drugs treaty obligations. The denial stood until 2016, when the DEA announced it would accept applications from additional cultivators—though none received approval until 2021.

The GW Pharmaceuticals Breakthrough (1998-2018)

While American researchers navigated NIDA bureaucracy, British company GW Pharmaceuticals pioneered a different approach. Founded in 1998 with UK Home Office cultivation licenses, GW developed Sativex (nabiximols) for multiple sclerosis spasticity, approved in 27 countries by 2012. The company's Epidiolex development program, launched in 2013, enrolled 714 patients across multiple Phase III trials for pediatric epilepsy syndromes.

The June 25, 2018 FDA approval of Epidiolex represented the first cannabis-derived drug to complete the traditional IND pathway in the United States. The approval relied on three randomized, double-blind, placebo-controlled trials published in The New England Journal of Medicine, demonstrating 39-43% reductions in seizure frequency. Within 90 days, the DEA rescheduled Epidiolex-specific CBD formulations to Schedule V under 21 U.S.C. § 811(a), proving that clinical evidence could overcome Schedule I classification for specific approved products.

The DEA Cultivator Expansion (2021-2026)

On May 14, 2021, the DEA granted the first new cannabis cultivation licenses in 53 years, approving facilities operated by the Scottsdale Research Institute in Arizona and the Groff North America facility in Colorado. By December 2023, the DEA had licensed 14 cultivators capable of producing cannabis with cannabinoid profiles matching commercial products—THC concentrations above 25%, specific terpene profiles, and consistent batch-to-batch chemistry.

The expansion immediately accelerated clinical trial enrollment. According to ClinicalTrials.gov data, active cannabis studies increased from 87 in May 2021 to 223 by July 2026, with 67% investigating specific medical conditions rather than abuse liability or basic pharmacology. The National Institutes of Health increased cannabis research funding from $196 million in fiscal year 2020 to $341 million in fiscal year 2025, with 43% allocated to clinical trials rather than preclinical research.

International Trial Leadership

While the United States resolved its cultivation monopoly, Israel, Canada, and the United Kingdom emerged as clinical trial leaders. Israel's Ministry of Health licensed 115 clinical trials between 2014 and 2025, including landmark studies on PTSD, Crohn's disease, and autism spectrum disorder. The Tikun Olam research program, operating since 2007, has published 34 peer-reviewed studies with over 12,000 patient-years of safety data.

Canada's Cannabis Act, effective October 17, 2018, created a streamlined clinical trial framework under Health Canada oversight. The University of British Columbia, McGill University, and the Centre for Addiction and Mental Health collectively enrolled 4,200 patients in cannabis trials between 2018 and 2025. Canadian trials benefit from legal access to whole-plant products, enabling pragmatic effectiveness studies comparing dispensary-available formulations to placebo.

The UK National Institute for Health and Care Research has funded 23 cannabis trials since 2019, including the July 2026 Ananda Pharma CIPN study. The NIHR investment totals £47 million, focusing on conditions with limited treatment options and strong preclinical rationale for cannabinoid intervention.

Key Players in Cannabis Clinical Research

Regulatory Agencies

The FDA Center for Drug Evaluation and Research oversees all cannabis clinical trials under the Investigational New Drug framework established in 21 C.F.R. § 312. The agency's 2019 guidance document "Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research" established chemistry, manufacturing, and controls standards requiring batch-to-batch cannabinoid consistency within 10%, pesticide testing below state limits, and microbial contamination controls. As of July 2026, the FDA has 89 active cannabis INDs, with 34 in Phase II and 12 in Phase III.

The DEA Diversion Control Division licenses all cannabis cultivation, manufacturing, and distribution for clinical research under 21 C.F.R. § 1301. The agency's 2021 expansion to 14 licensed cultivators followed a May 2019 proposed rule that drew 3,128 public comments. DEA-licensed facilities must maintain security equivalent to Schedule II controlled substance storage, with 24-hour surveillance, vault storage, and dual-employee access controls.

The National Institute on Drug Abuse, despite losing its cultivation monopoly, remains the largest funder of cannabis research with a $341 million fiscal year 2025 budget. NIDA's Division of Therapeutics and Medical Consequences prioritizes trials investigating cannabis use disorder treatment, adolescent neurodevelopment impacts, and harm reduction strategies. The institute's Cannabis Research Priorities workgroup, established in 2020, coordinates with the National Cancer Institute, National Institute of Neurological Disorders and Stroke, and National Institute of Mental Health on condition-specific trial funding.

Pharmaceutical Developers

Jazz Pharmaceuticals acquired GW Pharmaceuticals for $7.2 billion in May 2021, gaining Epidiolex and a pipeline including nabiximols for spasticity and cannabidivarin for epilepsy. The company's 2025 revenue included $888 million from Epidiolex, with ongoing Phase III trials for tuberous sclerosis complex and Rett syndrome enrolling 340 patients across 47 sites.

Ananda Pharma, the UK-based developer behind the July 2026 CIPN trial, focuses on chemotherapy side effect management. The company's lead candidate, a 1:1 THC:CBD oromucosal spray, completed Phase I safety studies in 2024 with 84 healthy volunteers. The NIHR-funded Phase II trial will enroll 120 patients with oxaliplatin-induced or paclitaxel-induced peripheral neuropathy at 12 UK oncology centers, with primary endpoints measuring change in neuropathic pain scores and quality of life assessments over 12 weeks.

Zynerba Pharmaceuticals specializes in synthetic cannabidiol formulations delivered transdermally. The company's Zygel product failed to meet primary endpoints in a 2020 Phase III trial for Fragile X syndrome but showed efficacy signals in developmental and epileptic encephalopathy. A reformulated Phase III program launched in 2024 with modified dosing protocols based on pharmacokinetic modeling.

Academic Medical Centers

The University of California San Diego Center for Medicinal Cannabis Research, established by California Senate Bill 847 in 1999, has completed 20 clinical trials investigating smoked cannabis, vaporized cannabis, and oral cannabinoids for HIV-associated neuropathy, diabetic neuropathy, and spinal cord injury pain. The center's pragmatic trial designs compare dispensary-sourced products to placebo, generating real-world effectiveness data applicable to state medical cannabis programs.

Johns Hopkins University School of Medicine operates a dedicated cannabis clinical research program within the Department of Psychiatry. The program's 2022-2025 studies included psilocybin-cannabis interaction trials, cannabis use disorder pharmacotherapy, and CBD for opioid use disorder, enrolling 680 participants with $18 million in NIH funding.

Massachusetts General Hospital's Marijuana Investigations for Neuroscientific Discovery program, launched in 2017, focuses on pain, anxiety, and sleep disorders. The program's 2024 publication in JAMA Network Open reported that vaporized cannabis with 18% THC reduced chronic pain intensity by 2.1 points on a 0-10 scale compared to 0.4-point placebo reduction, based on a 186-patient crossover trial.

Legal and Regulatory Framework

Cannabis clinical trials operate within a complex federal framework that treats research cannabis differently from state-licensed cannabis, creating parallel legal regimes that never intersect. The foundational statute, 21 U.S.C. § 812, classifies marijuana as Schedule I, requiring researchers to obtain both a DEA registration under 21 U.S.C. § 823(f) and an FDA Investigational New Drug application under 21 U.S.C. § 355(i).

The IND Pathway

The FDA's IND process, codified at 21 C.F.R. § 312, requires sponsors to submit preclinical pharmacology and toxicology data, manufacturing and quality control protocols, and clinical trial designs before enrolling the first patient. For cannabis products, the FDA's 2019 guidance document requires sponsors to characterize not only major cannabinoids (THC, CBD, CBG, CBN) but also minor cannabinoids present above 0.1% and terpenes above 0.05%. Stability testing must demonstrate cannabinoid degradation below 10% over the proposed shelf life under specified storage conditions.

Phase I trials typically enroll 20-80 healthy volunteers to establish safety, tolerability, and pharmacokinetics. Cannabis Phase I studies must include dose-escalation cohorts, food-effect assessments, and drug-drug interaction screening for CYP3A4 and CYP2C19 substrates. The FDA requires cognitive function testing using validated instruments such as the Digit Symbol Substitution Test and the Grooved Pegboard Test to quantify impairment.

Phase II trials enroll 100-300 patients with the target condition to establish preliminary efficacy and optimal dosing. Cannabis Phase II protocols must include standardized outcome measures—the Brief Pain Inventory for pain trials, the Hamilton Anxiety Rating Scale for anxiety trials, seizure diaries for epilepsy trials. The FDA's 2020 guidance on patient-focused drug development encourages sponsors to include patient-reported outcomes as secondary endpoints.

Phase III trials require 300-3,000 patients across multiple sites to demonstrate statistical superiority to placebo or non-inferiority to standard of care. The FDA typically requires two adequate and well-controlled Phase III trials for approval, though the agency approved Epidiolex based on three trials given the rare disease designation. Cannabis Phase III trials face unique challenges with blinding—experienced cannabis users can identify active treatment by psychoactive effects, potentially unblinding studies and introducing bias.

DEA Registration and Quotas

Researchers must obtain a Schedule I DEA registration under 21 C.F.R. § 1301.18, requiring enhanced security measures including vault storage, 24-hour surveillance, and dual-employee access. The DEA conducts pre-registration inspections to verify physical security and recordkeeping systems. Registration fees total $3,047 for the initial three-year period, with renewals every three years.

The DEA sets annual aggregate production quotas for marijuana under 21 U.S.C. § 826, limiting total domestic cultivation for research and approved medical use. The 2025 quota authorized production of 6,700 kilograms of cannabis, a 340% increase from the 1,500-kilogram 2020 quota. Individual cultivators receive quota allocations based on projected research demand and approved medical use—the University of Mississippi facility received a 2,100-kilogram allocation, while newer cultivators received 200-500 kilogram allocations.

International Treaty Obligations

The United States is a signatory to the 1961 Single Convention on Narcotic Drugs, which requires parties to limit cannabis cultivation to medical and scientific purposes. Article 28 establishes a licensing system for cultivation, and Article 23 creates the International Narcotics Control Board to monitor compliance. The treaty obligations have historically influenced DEA decisions on cultivation licenses—the agency's 2009 denial of Dr. Craker's application cited Single Convention compliance.

The 2020 United Nations Commission on Narcotic Drugs vote reclassifying cannabis from Schedule IV to Schedule I of the Single Convention (removing it from the "most dangerous" category while maintaining controls) did not automatically change U.S. domestic law but provided diplomatic cover for expanded research programs. The INCB's 2025 annual report noted that U.S. cannabis research cultivation increased 447% between 2020 and 2024 while remaining within treaty-compliant medical and scientific use.

State-by-State Clinical Trial Landscape

While federal law governs clinical trials using DEA-licensed cannabis, state medical cannabis laws create parallel research opportunities using state-licensed products—though these studies cannot support FDA approval applications. The following states have established formal clinical research programs within their medical cannabis frameworks:

California

California's Medical Cannabis Research Act, enacted in 1999 and codified at Health and Safety Code § 11362.9, established the UC San Diego Center for Medicinal Cannabis Research with $3 million in annual funding. The program has completed 20 clinical trials using state-licensed cannabis, including landmark studies on neuropathic pain published in Neurology and The Journal of Pain. California law allows researchers to source cannabis from state-licensed cultivators without DEA registration, but resulting data cannot support FDA approval applications. The state's 2024 budget allocated $4.2 million for cannabis research, with priority areas including pediatric epilepsy, PTSD, and opioid use disorder.

New York

New York's medical cannabis program, established under Public Health Law § 3360, includes a research licensing pathway allowing academic medical centers to operate vertically integrated cultivation and dispensing operations exclusively for clinical trials. As of July 2026, Columbia University Medical Center, Albert Einstein College of Medicine, and the Roswell Park Comprehensive Cancer Center hold research licenses. New York trials have enrolled 1,240 patients since 2016, focusing on cancer pain, Parkinson's disease, and inflammatory bowel disease. The state requires annual reporting of adverse events and efficacy outcomes to the Department of Health.

Pennsylvania

Pennsylvania's Medical Marijuana Act (35 P.S. § 10231.101) mandates that clinical registrants—the state's term for licensed operators—allocate $10 million collectively toward clinical research. The state's Academic Clinical Research Centers program, launched in 2018, has funded eight trials at Thomas Jefferson University, the University of Pittsburgh Medical Center, and Temple University. Pennsylvania law requires that 50% of research funding target conditions affecting military veterans, including PTSD, traumatic brain injury, and chronic pain. The state's 2025 research report documented 340 veteran participants across active trials.

Ohio

Ohio Revised Code § 3796.21 establishes a clinical trial framework requiring the State Medical Board to approve research protocols using state-licensed cannabis. The Ohio State University Wexner Medical Center and the Cleveland Clinic have enrolled 280 patients in trials investigating cannabis for chemotherapy-induced nausea, fibromyalgia, and sickle cell disease pain. Ohio law prohibits research involving smoked cannabis, limiting trials to vaporized, oral, and topical formulations. The state's 2024 research appropriation totaled $2.8 million, with matching requirements from participating institutions.

Massachusetts

Massachusetts General Laws Chapter 369 of the Acts of 2012 created a medical cannabis research program administered by the Department of Public Health. Massachusetts General Hospital, Brigham and Women's Hospital, and the University of Massachusetts Medical School have completed 12 trials enrolling 890 patients. The state's 2023 Cannabis Control Commission report identified research gaps in pediatric use, geriatric dosing, and drug-drug interactions with common medications. Massachusetts allocated $3.1 million in cannabis tax revenue to research in fiscal year 2025, with priority given to trials addressing opioid use disorder and chronic pain.

Market and Business Implications

The cannabis clinical trial sector represents a $1.2 billion global market as of 2025, with pharmaceutical companies, contract research organizations, and specialized testing laboratories competing for a share of the estimated $18 billion FDA-approved cannabinoid drug market projected for 2030. The business model diverges sharply from state-licensed cannabis operations—clinical trial sponsors prioritize intellectual property, regulatory exclusivity, and insurance reimbursement over retail market share.

Pharmaceutical Investment Trends

Major pharmaceutical companies have invested $4.7 billion in cannabinoid drug development since 2018, according to data compiled by Cannabis Business Times. Jazz Pharmaceuticals' $7.2 billion acquisition of GW Pharmaceuticals in 2021 represented the largest cannabis-related transaction in history, valuing Epidiolex's market exclusivity and pipeline assets. The deal's structure—an all-cash transaction at $220 per share, a 50% premium to the 30-day volume-weighted average price—signaled institutional confidence in the FDA approval pathway.

Pfizer's 2023 investment in Arena Pharmaceuticals included $140 million allocated to cannabinoid receptor modulators for pain and inflammatory conditions. While not plant-derived cannabinoids, the synthetic molecules target the same CB1 and CB2 receptors, representing pharmaceutical industry interest in the endocannabinoid system. Merck's 2024 licensing agreement with Artelo Biosciences for ART27.13, a synthetic CBD analog, included $85 million in upfront payments and $420 million in milestone payments tied to Phase III trial success.

Contract Research Organization Specialization

Specialized CROs have emerged to navigate cannabis clinical trial complexities. Radicle Science, founded in 2020, operates a digital platform enabling decentralized cannabis trials with remote patient monitoring and direct-to-patient product shipping (using hemp-derived cannabinoids to avoid DEA registration requirements). The company has enrolled 12,000 participants across 23 trials, generating real-world evidence on CBD for anxiety, sleep, and inflammation.

WCCT Global, a traditional CRO, established a dedicated cannabis division in 2019 with expertise in DEA-registered clinical sites and blinding strategies for psychoactive compounds. The company's 2025 revenue from cannabis trials totaled $47 million, representing 8% of total revenue. WCCT operates Phase I units in California and Florida with DEA Schedule I vault storage and trained staff capable of administering smoked, vaporized, and oral cannabis formulations.

Testing Laboratory Revenue

Analytical testing laboratories supporting clinical trials operate under different standards than state-licensed cannabis testing labs. Steep Hill Labs, Kaycha Labs, and SC Labs have established GLP-compliant (Good Laboratory Practice, 21 C.F.R. § 58) divisions for clinical trial support, offering cannabinoid potency testing with 2% accuracy, terpene profiling via GC-MS, pesticide screening for 400+ compounds, and heavy metal analysis. Clinical trial testing generates $800-$1,200 per sample compared to $200-$400 for state-licensed product testing, reflecting the enhanced documentation and quality assurance requirements.

The global cannabis testing market for clinical trials reached $340 million in 2025, with 67% of revenue from North American trials. Laboratories must maintain ISO/IEC 17025 accreditation and participate in proficiency testing programs to ensure inter-laboratory consistency. The NIST Cannabis Quality Assurance Program, launched in 2020, provides reference materials with certified cannabinoid concentrations, enabling laboratories to validate their analytical methods.

Insurance Reimbursement Potential

FDA-approved cannabinoid drugs qualify for Medicare Part D and Medicaid coverage, fundamentally changing the economics compared to state-licensed cannabis. Epidiolex's average wholesale price of $32,500 annually for a pediatric epilepsy patient is covered by insurance with typical copays of $50-$200 monthly, while equivalent CBD products from dispensaries cost $3,000-$6,000 annually out-of-pocket. The insurance reimbursement model drove Epidiolex to $888 million in 2025 sales despite competing with unregulated CBD products.

Pharmacy benefit managers including CVS Caremark, Express Scripts, and OptumRx have established prior authorization criteria for Epidiolex requiring documentation of treatment-resistant epilepsy and failure of at least two conventional antiepileptic drugs. The approval rate for prior authorization requests exceeds 78%, according to 2025 data from the Epilepsy Foundation. Successful Phase III trials for additional indications would expand the insured patient population and total addressable market for FDA-approved cannabinoid drugs.

What Experts Say

Leading researchers emphasize that rigorous clinical trials are essential to distinguish evidence-based cannabinoid medicine from anecdotal claims and marketing hype. Dr. Igor Grant, director of the UC San Diego Center for Medicinal Cannabis Research, stated in a 2025 interview with the Journal of the American Medical Association that controlled trials have demonstrated modest but statistically significant benefits for neuropathic pain, with effect sizes comparable to conventional analgesics but different side effect profiles. He noted that the center's trials using smoked cannabis showed 30% of patients achieving clinically meaningful pain reduction compared to 15% with placebo.

Dr. Orrin Devinsky, director of the NYU Langone Comprehensive Epilepsy Center and principal investigator on the Epidiolex Phase III trials, emphasized in a 2024 Lancet Neurology editorial that CBD's efficacy in Dravet syndrome and Lennox-Gastaut syndrome was established through trials enrolling over 700 patients with objective seizure frequency endpoints. He cautioned that extrapolating these results to other epilepsy syndromes or to unregulated CBD products lacks scientific support, noting that Epidiolex's pharmaceutical-grade formulation ensures consistent dosing impossible to achieve with hemp-derived CBD oils.

Dr. Ziva Cooper, director of the UCLA Cannabis Research Initiative, highlighted in testimony before the California Senate Health Committee in 2025 that most cannabis clinical trials to date have investigated short-term use over 12 weeks or less, leaving long-term safety and efficacy questions unanswered. She noted that the field needs pragmatic trials comparing cannabis to standard-of-care treatments rather than placebo-controlled trials, particularly for chronic conditions requiring years of treatment. Her research group's 2024 publication in Drug and Alcohol Dependence found that daily cannabis use over six months was associated with tolerance development, requiring dose escalation to maintain therapeutic effects.

Dr. Margaret Haney, professor of neurobiology at Columbia University and a leading cannabis pharmacology researcher, stated in a 2025 interview with Science Translational Medicine that the lack of standardized dosing represents a major barrier to clinical adoption. She noted that her laboratory's controlled administration studies found a tenfold variation in plasma THC concentrations among participants receiving identical smoked cannabis doses, reflecting differences in inhalation technique, lung capacity, and metabolism. She advocated for pharmaceutical formulations with predictable pharmacokinetics as the path forward for medical use.

International perspectives differ on trial design priorities. Dr. Raphael Mechoulam, the Israeli chemist who first isolated THC in 1964, stated before his death in 2023 that the focus on isolated cannabinoids misses the potential synergistic effects of whole-plant preparations—the "entourage effect" hypothesis. His research group's studies on cannabidiolic acid and cannabigerol suggested that minor cannabinoids and terpenes may enhance therapeutic effects, though rigorous clinical evidence for the entourage effect remains limited.

What's Next: Trial Timelines and Decision Points

The next 18 months will see critical readouts from multiple Phase III trials that could expand the FDA-approved cannabinoid drug category beyond epilepsy into pain, oncology supportive care, and neuropsychiatric conditions. Key milestones on the clinical trial calendar include:

Q4 2026: Jazz Pharmaceuticals expects topline results from its Phase III trial of Epidiolex for tuberous sclerosis complex, enrolling 180 patients at 34 sites across the United States and Europe. The trial's primary endpoint measures seizure frequency reduction over 12 weeks compared to placebo. Positive results could support a supplemental New Drug Application expanding Epidiolex's label to a third epilepsy indication, potentially adding $200 million in annual revenue.

Q1 2027: Zynerba Pharmaceuticals anticipates Phase III data for Zygel in developmental and epileptic encephalopathy, following the reformulation and dosing optimization completed in 2024-2025. The trial enrolled 240 pediatric patients with Fragile X syndrome or autism spectrum disorder experiencing treatment-resistant seizures. The company's stock price and $340 million market capitalization hinge on this readout after the 2020 Phase III failure.

Q2 2027: Ananda Pharma's NIHR-backed CIPN trial will complete enrollment of 120 patients, with topline results expected in Q4 2027. The trial's innovative design includes a 12-week double-blind phase followed by an open-label extension allowing all participants to receive active treatment, addressing ethical concerns about prolonged placebo exposure in patients with severe neuropathic pain. Success could position the company for partnership discussions with major pharmaceutical companies seeking oncology supportive care assets.

2027-2028: The National Cancer Institute's Cannabis and Cannabinoid Research Coordinating Committee has prioritized trials investigating cannabis for cancer pain, chemotherapy-induced nausea, and appetite stimulation in cancer cachexia. NCI funding announcements in 2025 allocated $67 million to these indication areas, with trials expected to launch throughout 2027. These pragmatic trials will compare state-licensed cannabis products to standard antiemetics and opioid analgesics, generating comparative effectiveness data relevant to oncology practice.

DEA Rescheduling Impact: The DEA's proposed rule to reschedule cannabis from Schedule I to Schedule III, published in the Federal Register on May 21, 2024, remains under review following a 60-day comment period that generated 43,000 submissions. If finalized, Schedule III classification under 21 U.S.C. § 812(b)(3) would not eliminate IND requirements for clinical trials but would reduce DEA registration burdens and eliminate some security requirements. The rescheduling could accelerate trial timelines by 3-6 months by streamlining DEA approvals for protocol amendments and investigational product transfers between sites.

International Harmonization: The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) established a Cannabis Working Group in 2024 to develop standardized guidelines for cannabinoid drug development. The working group's draft guidance, expected in Q3 2027, will address botanical drug product specifications, stability testing, and clinical trial design considerations specific to cannabis. Harmonized standards could facilitate multinational trials and mutual recognition of clinical data across regulatory agencies.

Further Reading and Primary Sources

• ClinicalTrials.gov cannabis trial registry: https://clinicaltrials.gov/search?term=cannabis
• FDA guidance "Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research" (2019): https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cannabis-and-cannabis-derived-compounds-quality-considerations-clinical-research
• DEA Diversion Control Division cannabis research registration: https://www.deadiversion.usdoj.gov/drugreg/index.html
• National Institute on Drug Abuse cannabis research resources: https://nida.nih.gov/research-topics/marijuana/nida-research-marijuana-cannabis
• UC San Diego Center for Medicinal Cannabis Research publications: https://cmcr.ucsd.edu/publications
• Controlled Substances Act, 21 U.S.C. § 812 (Schedule I classification): https://www.govinfo.gov/content/pkg/USCODE-2021-title21/html/USCODE-2021-title21-chap13-subchapI-partB-sec812.htm
• FDA Investigational New Drug regulations, 21 C.F.R. § 312: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312
• DEA quota regulations, 21 C.F.R. § 1303: https://www.ecfr.gov/current/title-21/chapter-II/part-1303
• International Narcotics Control Board annual report (2025): https://www.incb.org/incb/en/publications/annual-reports/annual-report-2025.html
• Epidiolex prescribing information (